Ishara Investments LP Invests $2.68 Million in United Therapeutics Corporation $UTHR

Ishara Investments LP bought a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,500 shares of the biotechnology company’s stock, valued at approximately $2,680,000. United Therapeutics accounts for 3.1% of Ishara Investments LP’s portfolio, making the stock its 10th largest position.

Several other hedge funds also recently made changes to their positions in UTHR. Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics in the 3rd quarter worth $317,617,000. Norges Bank acquired a new stake in shares of United Therapeutics in the 4th quarter worth $293,418,000. Avoro Capital Advisors LLC lifted its stake in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Janus Henderson Group PLC lifted its stake in shares of United Therapeutics by 75.1% in the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the period. Finally, Baillie Gifford & Co. acquired a new stake in shares of United Therapeutics in the 4th quarter worth $157,390,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.6%

Shares of UTHR opened at $551.47 on Thursday. The company has a 50-day simple moving average of $565.95 and a 200-day simple moving average of $522.96. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The company has a market capitalization of $23.41 billion, a PE ratio of 20.36, a P/E/G ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter last year, the business posted $6.63 earnings per share. The business’s revenue was down 1.6% compared to the same quarter last year. On average, research analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current year.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,540,358.40. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 636,168 shares of company stock worth $359,249,237. Company insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research analyst reports. HC Wainwright increased their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Bank of America increased their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.